GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00709979 | Breast | Precancer | neuron death | 50/1080 | 361/18723 | 7.75e-09 | 5.70e-07 | 50 |
GO:00514029 | Breast | Precancer | neuron apoptotic process | 38/1080 | 246/18723 | 2.68e-08 | 1.75e-06 | 38 |
GO:00509006 | Breast | Precancer | leukocyte migration | 47/1080 | 369/18723 | 2.82e-07 | 1.39e-05 | 47 |
GO:00022629 | Breast | Precancer | myeloid cell homeostasis | 27/1080 | 157/18723 | 3.10e-07 | 1.49e-05 | 27 |
GO:00457859 | Breast | Precancer | positive regulation of cell adhesion | 52/1080 | 437/18723 | 5.74e-07 | 2.49e-05 | 52 |
GO:00511019 | Breast | Precancer | regulation of DNA binding | 22/1080 | 118/18723 | 9.28e-07 | 3.71e-05 | 22 |
GO:00341019 | Breast | Precancer | erythrocyte homeostasis | 23/1080 | 129/18723 | 1.20e-06 | 4.60e-05 | 23 |
GO:19012149 | Breast | Precancer | regulation of neuron death | 41/1080 | 319/18723 | 1.27e-06 | 4.80e-05 | 41 |
GO:00435237 | Breast | Precancer | regulation of neuron apoptotic process | 31/1080 | 212/18723 | 1.69e-06 | 6.08e-05 | 31 |
GO:00433887 | Breast | Precancer | positive regulation of DNA binding | 14/1080 | 56/18723 | 2.46e-06 | 8.35e-05 | 14 |
GO:00510989 | Breast | Precancer | regulation of binding | 44/1080 | 363/18723 | 2.59e-06 | 8.65e-05 | 44 |
GO:00300999 | Breast | Precancer | myeloid cell differentiation | 45/1080 | 381/18723 | 4.00e-06 | 1.25e-04 | 45 |
GO:00018196 | Breast | Precancer | positive regulation of cytokine production | 52/1080 | 467/18723 | 4.18e-06 | 1.29e-04 | 52 |
GO:00487329 | Breast | Precancer | gland development | 49/1080 | 436/18723 | 6.11e-06 | 1.73e-04 | 49 |
GO:0050727 | Breast | Precancer | regulation of inflammatory response | 44/1080 | 386/18723 | 1.26e-05 | 3.22e-04 | 44 |
GO:00103323 | Breast | Precancer | response to gamma radiation | 13/1080 | 56/18723 | 1.35e-05 | 3.38e-04 | 13 |
GO:00421107 | Breast | Precancer | T cell activation | 52/1080 | 487/18723 | 1.37e-05 | 3.42e-04 | 52 |
GO:00508707 | Breast | Precancer | positive regulation of T cell activation | 29/1080 | 216/18723 | 1.94e-05 | 4.58e-04 | 29 |
GO:00436273 | Breast | Precancer | response to estrogen | 15/1080 | 75/18723 | 2.06e-05 | 4.83e-04 | 15 |
GO:00106348 | Breast | Precancer | positive regulation of epithelial cell migration | 25/1080 | 176/18723 | 2.75e-05 | 6.21e-04 | 25 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa046597 | Prostate | BPH | Th17 cell differentiation | 36/1718 | 108/8465 | 9.75e-04 | 4.47e-03 | 2.76e-03 | 36 |
hsa0492814 | Prostate | BPH | Parathyroid hormone synthesis, secretion and action | 33/1718 | 106/8465 | 5.30e-03 | 1.75e-02 | 1.08e-02 | 33 |
hsa0465912 | Prostate | BPH | Th17 cell differentiation | 36/1718 | 108/8465 | 9.75e-04 | 4.47e-03 | 2.76e-03 | 36 |
hsa0492815 | Prostate | BPH | Parathyroid hormone synthesis, secretion and action | 33/1718 | 106/8465 | 5.30e-03 | 1.75e-02 | 1.08e-02 | 33 |
hsa0465922 | Prostate | Tumor | Th17 cell differentiation | 36/1791 | 108/8465 | 2.11e-03 | 8.42e-03 | 5.22e-03 | 36 |
hsa0492822 | Prostate | Tumor | Parathyroid hormone synthesis, secretion and action | 35/1791 | 106/8465 | 2.89e-03 | 1.07e-02 | 6.67e-03 | 35 |
hsa0465932 | Prostate | Tumor | Th17 cell differentiation | 36/1791 | 108/8465 | 2.11e-03 | 8.42e-03 | 5.22e-03 | 36 |
hsa0492832 | Prostate | Tumor | Parathyroid hormone synthesis, secretion and action | 35/1791 | 106/8465 | 2.89e-03 | 1.07e-02 | 6.67e-03 | 35 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GATA3 | SNV | Missense_Mutation | | c.881T>A | p.Met294Lys | p.M294K | P23771 | protein_coding | deleterious(0) | possibly_damaging(0.692) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
GATA3 | SNV | Missense_Mutation | | c.1095N>T | p.Arg365Ser | p.R365S | P23771 | protein_coding | deleterious(0.04) | probably_damaging(1) | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD |
GATA3 | SNV | Missense_Mutation | | c.983N>A | p.Leu328His | p.L328H | P23771 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A24P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GATA3 | SNV | Missense_Mutation | novel | c.989G>A | p.Arg330Lys | p.R330K | P23771 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-B6-A40C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | cyclophosphamide | SD |
GATA3 | SNV | Missense_Mutation | | c.1071G>T | p.Met357Ile | p.M357I | P23771 | protein_coding | deleterious(0.01) | probably_damaging(0.925) | TCGA-BH-A0BQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
GATA3 | SNV | Missense_Mutation | novel | c.992N>A | p.Arg331Lys | p.R331K | P23771 | protein_coding | deleterious(0.04) | probably_damaging(0.946) | TCGA-BH-A0C7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
GATA3 | SNV | Missense_Mutation | | c.881N>A | p.Met294Lys | p.M294K | P23771 | protein_coding | deleterious(0) | possibly_damaging(0.692) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
GATA3 | SNV | Missense_Mutation | | c.845N>G | p.His282Arg | p.H282R | P23771 | protein_coding | deleterious(0) | possibly_damaging(0.882) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
GATA3 | SNV | Missense_Mutation | | c.881N>A | p.Met294Lys | p.M294K | P23771 | protein_coding | deleterious(0) | possibly_damaging(0.692) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
GATA3 | SNV | Missense_Mutation | | c.356A>T | p.Lys119Met | p.K119M | P23771 | protein_coding | deleterious(0) | probably_damaging(0.936) | TCGA-BH-A18M-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2625 | GATA3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | mercaptopurine | MERCAPTOPURINE | 24141364 |
2625 | GATA3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | pegaspargase | PEGASPARGASE | 24141364 |
2625 | GATA3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | leucovorin | LEUCOVORIN | 24141364 |
2625 | GATA3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | vincristine | VINCRISTINE | 24141364 |
2625 | GATA3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | thioguanine | THIOGUANINE | 24141364 |
2625 | GATA3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | asparaginase | ASPARAGINASE | 24141364 |
2625 | GATA3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | prednisone | PREDNISONE | 24141364 |
2625 | GATA3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | methotrexate | METHOTREXATE | 24141364 |
2625 | GATA3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | dexamethasone | DEXAMETHASONE | 24141364 |
2625 | GATA3 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR | | doxorubicin | DOXORUBICIN | 24141364 |